PVR and neoplasm: TIGIT is mainly expressed on tumor-infiltrating effector T cells, regulatory T cells, and NK cells within various tumor types, and exerts its immunosuppressive effects in T cells by competing with the CD226 receptor for binding to the shared ligands CD155 and CD112 [117,118,119,120,121,122].